# Tiny Packages for Delivering Gene-Targeting Drugs to Specific Cells

> This patent describes a method to create tiny, targeted packages made of lipids and proteins that can deliver specific gene-modifying drugs, like antisense oligonucleotides, directly to certain cells in the body.

- **Patent:** US 10307490
- **Original title:** Lipid nanoparticle compositions for antisense oligonucleotides delivery
- **Owner:** The Ohio State University
- **Granted:** 2019
- **Status:** Active
- **Times cited:** 3
- **Field:** biotech, pharmaceutical, nanotechnology, gene_editing

## What it does

This patent describes a special type of tiny package called a lipid-coated albumin nanoparticle (LCAN) designed to deliver therapeutic agents. The LCAN is built around a core that is positively charged and contains an albumin-polycation conjugate, as specified in claim 1. This core can encapsulate a therapeutic agent, such as an antisense oligonucleotide (ASO) that targets genes like Akt-1 or HIF-1, as detailed in claims 2 and 3. The entire core is then wrapped in a positively-charged lipid layer, called a cationic liposome. Crucially, the nanoparticle also includes a 'targeting agent' (claim 1), which acts like a homing beacon to guide the package to specific cells or tissues, using molecules like RGD peptides or folate (claim 8). For example, this system could deliver an ASO to cancer cells, blocking a gene that helps them grow, while minimizing effects on healthy cells.

## What it does NOT cover

- Does not cover drug delivery systems that do not use a lipid-coated albumin nanoparticle (LCAN) structure as defined in claim 1.
- Does not cover nanoparticles where the core is not net positively-charged or does not contain an albumin-polycation conjugate.
- Does not cover delivery systems that lack a specific targeting agent to direct the nanoparticle to certain cells.
- Does not cover lipid nanoparticles that are purely anionic or neutral in charge, as the claims specify a 'cationic liposome' and a 'net positively-charged core'.
- Does not cover delivery of therapeutic agents that are not encapsulated within the core of the nanoparticle.

## The clever bit

The clever part is combining a stable, positively-charged protein-polycation core with a cationic lipid shell and a specific targeting agent. This creates a robust, targeted nanoparticle that can effectively encapsulate and deliver negatively-charged therapeutic agents like ASOs, ensuring they reach their intended cellular destination.

## Real-world examples

1. Targeted cancer therapies using nanoparticles
2. Gene therapy delivery systems
3. Antisense oligonucleotide (ASO) drug formulations
4. mRNA vaccine delivery (using lipid nanoparticles)
5. Drug delivery systems for inflammatory diseases

## Why it matters

This patent is important because it describes a way to make drug delivery more precise. By using 'targeting agents' and encapsulating drugs in stable nanoparticles, it aims to deliver medicines directly to diseased cells while avoiding healthy ones. This approach is crucial for therapies like antisense oligonucleotides (ASOs), which need to reach specific cells to work effectively and reduce unwanted side effects. It contributes to the broader field of nanomedicine, which seeks to revolutionize how drugs are administered.

## Frequently asked questions

### What does Tiny Packages for Delivering Gene-Targeting Drugs to Specific Cells cover?

This patent describes a method to create tiny, targeted packages made of lipids and proteins that can deliver specific gene-modifying drugs, like antisense oligonucleotides, directly to certain cells in the body.

### Who owns patent US 10307490?

The Ohio State University owns this patent, granted in 2019.

### When does this patent expire?

This patent is expected to expire on May 23, 2033, when the invention enters the public domain.

### What is patent US 10307490 cited by?

This patent has been cited by 3 later patents that build on its ideas.

### What problem does this patent solve?

This patent is important because it describes a way to make drug delivery more precise. By using 'targeting agents' and encapsulating drugs in stable nanoparticles, it aims to deliver medicines directly to diseased cells while avoiding healthy ones. This approach is crucial for therapies like antisense oligonucleotides (ASOs), which need to reach specific cells to work effectively and reduce unwanted side effects. It contributes to the broader field of nanomedicine, which seeks to revolutionize how drugs are administered.

### What does this patent NOT cover?

Does not cover drug delivery systems that do not use a lipid-coated albumin nanoparticle (LCAN) structure as defined in claim 1.

**Full plain-English explainer:** https://patentbrief.org/patent/us/10307490/lipid-nanoparticle-compositions-for-antisense-oligonucleotides-delivery

**Original patent:** https://patents.google.com/patent/US10307490

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._


## Related patents

Semantically similar inventions in the PatentBrief corpus:

- [Tiny Fat Bubbles That Deliver Drugs Directly to the Liver](https://patentbrief.org/patent/us/11464870/lipid-nanoparticles-for-in-vivo-drug-delivery-and-uses-thereof) — This patent describes special tiny fat bubbles, called lipid nanoparticles, designed to carry gene therapy drugs efficiently and specifically to liver cells for treating liver diseases.
- [Tiny Bubbles for Delivering Medicine](https://patentbrief.org/patent/us/20250235403/compositions-and-methods-of-the-delivery-of-active-agents-including-nucleic-acid) — This patent describes tiny, bubble-like structures made of fats that can carry medicine, like genetic material, and release it effectively inside the body by changing their structure in slightly acidic environments.
- [How to Build Tiny Lipid Capsules to Deliver Genetic Medicines](https://patentbrief.org/patent/us/10155945/method-of-producing-lipid-nanoparticles-for-drug-delivery) — A precise method for creating small, stable lipid bubbles that safely carry genetic material like siRNA into cells for medical treatment.
- [How Special Nanoparticles Deliver Cancer Drugs Directly to Tumors](https://patentbrief.org/patent/us/20190046446/apo-e-modified-lipid-nanoparticles-for-drug-delivery-to-targeted-tissues-and-the) — This patent describes tiny fat-based particles, called lipid nanoparticles, designed to carry cancer drugs directly to tumor cells using a special protein (ApoE3) on their surface, avoiding a common, potentially problematic ingredient.
- [Targeting Drugs to Specific Body Tissues Using ApoE3-Coated Nanoparticles](https://patentbrief.org/patent/us/20190307892/targeted-drug-delivery-and-therapeutic-methods-using-apo-e-modified-lipid-nanopa) — This patent describes a method to deliver drugs or diagnostic agents precisely to target cells or tissues, including the brain, by packaging them inside tiny fat particles (lipid nanoparticles) coated with a special protein called ApoE3.
